NeuroSense Therapeutics, Ltd. (NASDAQ: NRSN), a leading clinical-stage biotechnology company focused on developing treatments for severe neurodegenerative diseases, today announced promising new ...

Spark Therapeutics Inc. has presented a proprietary adeno-associated viral (AAV) vector expressing an artificial miRNA targeting human α-synuclein (α-Syn) mRNA. Accumulation of misfolded and insoluble ...

This Review discusses cell therapy as an alternative therapeutic strategy for liver transplantation, the pros and cons, and the future technological potential.

The goal of therapy is to rework our stories in a way that is helpful and meaningful to us.